Purpose: In recent years, considerable progress has been made in the use of gallium-68 labeled receptor-specific peptides for imaging oncologic diseases. The objective was to examine the stability and pharmacokinetics of [
Introduction
In recent years, considerable progress has been made in developing Ga-68 labeled small molecules such as peptides, for imaging oncologic diseases [1] [2] [3] [4] [5] . To facilitate Ga-68 labeling effectively, a variety of bifunctional chelating agents (BFCAs) have been developed and used [6] [7] [8] [9] [10] . M a n y s t u d i e s h a v e s h o w n N O D A G A ( 1 , 4 , 7 -triazacyclononane-1-glutamic acid-4,7-diacetic acid) superiority over other BFCAs such as DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), or HBED-CC (N,N ′-bis-[2-hydroxy-5-(carboxyethyl) benzyl] ethylenediamine-N,N′-diacetic acid) [11, 12] . Our previous study has reported that NODAGA has faster labeling kinetics and permits Ga-68 labeling at room temperature under acidic conditions [13] . In vivo stability governs the success of these conjugates in animal and patient imaging. However, only a few investigators reported on the stability of various Ga-68 labeled agents. In this investigation, we have examined the stability of [ 68 Ga ]NODAGA and DOTA-peptide conjugates and studied their pharmacokinetics in tumor xenografts.
Our laboratory has successfully designed and characterized a peptide-chelator conjugate (TP-3805) which has a high affinity for VPAC [combined for vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP)] receptors. Radiolabeled with copper-64, TP-3805 has been used for PET imaging of breast cancer (BC) and prostate cancer (PC) in humans [14, 15] . This peptide is an analog of pituitary adenylate cyclase-activating peptide (PACAP)-a 27 amino acid peptide which has a high affinity for VPAC receptors expressed on (100 %) malignant BC and PC cells [16] [17] [18] [19] [20] [21] . VPAC receptors which encode a G protein involved in cell proliferation and cell differentiation are also expressed in high density on the cell surface of cancers such as those of urinary bladder (100 %), colon (96 %), pancreas (65 %), lung (58 %), stomach (54 %), and liver (49 %) [22] [23] [24] . Only a few VPAC receptors are expressed on stroma, normal cells, and benign masses.
With the virtue of Germanium-68 ( 68 Ge)/[ 68 Ga ] generator availability and high positron emission (β+, 88 %), Ga-68 is a suitable radionuclide for diagnostic PET imaging. The short physical half-life also induces a low radiation burden to the patients, which strengthens its choice for imaging [25] [26] [27] . For the stability and pharmacokinetic studies, we chose TP-3805 as a model peptide, conjugated with NODAGA and DOTA, and chelated with . This study provides the details of ex vivo and in vivo stability, cell binding assay, positron emission tomography/computed tomography (PET/ CT) imaging, and tissue distribution in mice bearing BT474 xenografts.
Materials and Methods

Reagents
Fmoc amino acids, solvents, and reagents for peptidechelator synthesis were purchased from Fluka chemicals (St. Louis, MO). The bifunctional chelator DOTA was purchased from Macrocyclics (Dallas, TX) and NODAGA from Chematech (Dijon, France). Diethylenetriamine pentaacetic acid (DTPA), ferric chloride (FeCl 3 ), calcium chloride (CaCl 2 ), zinc chloride (ZnCl 2 ), hydrochloric acid solutions, and acetone were purchased from Thermo Fisher Scientific (Waltham, MA). Transferrin was obtained from Sigma-Aldrich (St. Louis, MO) and cation exchange columns from Agilent Technologies (Santa Clara, CA). Sodium chloride solution (0.9 %) was prepared in our laboratory using deionized water. All reagents were of analytical grade and were used without further purification.
Instruments
The PACAP analog with C-terminal NODAGA and DOTA chelators was synthesized on a Wang resin using a PS3 peptide synthesizer (Protein Technologies, Tucson, AZ, USA) and purified using a preparative reversed phase C18 column (Grace Davison, Deerfield, IL, USA) on a highpressure liquid chromatography (HPLC) system (Shimadzu Corporation, Kyoto, Japan) equipped with gradient pumps and ultraviolet/visible (UV/Vis) detector. Radiochemical purity was monitored by radio-HPLC (Shimadzu Corporation, Kyoto, Japan) equipped with gradient pumps and UV/ Vis detector, a sodium iodide-thallium [NaI(Tl)] radioactivity monitor, and a rate meter. Mass spectrometry (MS) was performed on a 4800 matrix-assisted laser desorption/ ionization-time of flight (MALDI-TOF) instrument (SciEx, Framingham, MA). Instant thin layer chromatography (ITLC) was performed on pre-coated aluminum sheets with silica gel which were purchased from Merck (Kenilworth, NJ) and radioactivity was measured on a Wizard 2 2480 automatic gamma counter (Perkin Elmer, Waltham, MA). The pH of the solutions was measured using either a pH meter (Sartorius, Gottingen, Germany) or pH strips (Fisher Scientific Inc. 
Synthesis of Peptide-Chelator Conjugate
Using methods previously described [13] , Fmoc-Lys(ivDde) was first introduced as the first residue on the resin, forming the C terminus of the peptide, followed by 4-aminobutyric acid (γ-Aba). The 27-amino-acid long PACAP sequence was then extended C→N by standard Fmoc coupling with the final histidyl residue being a t-Boc-protected His(Trt) derivative. The t-Boc capping function was necessary to ensure that the N-terminal amino group remained protected during subsequent deprotection and coupling cycles performed at the γ-amino group of the C-terminal lysine. The ivDde group at the C-terminal lysine was then selectively removed with 2 % hydrazine, followed by coupling with NODAGA/DOTA. The peptide-chelator was then cleaved from the resin, deprotected using CF 3 CO 2 H/water/phenol/ thioanisole/ethanedithiol (82.5/5/5/5/2.5), and precipitated with diethyl ether. The crude peptide was purified to homogeneity by HPLC using a preparative C18 reversed phase column. The purified peptide-chelators were characterized by MALDI-MS. Ga ]GaCl 3 were incubated at 90°C for 30 min and pH was adjusted to 7.2 ± 0.2 with 0.1 M NaOH (post-incubation). Radiochemical purity was monitored by radio-HPLC on a reversed phase C18 micro-bound column (4.6 mm × 250 mm, 5 μm, ZORBAX 300SB-C-18) eluted with a gradient from 10 % CH 3 CN in aqueous 0.1 % CF 3 CO 2 H to 100 % CH 3 CN in 0.1 % CF 3 CO 2 H at a flow rate of 1 ml/min over 28 min. Specific activity was measured after the end of preparation (approximately 30 min after the start of synthesis) and decay corrected for the time elapsed (30 min) after the start of synthesis.
Radiochemistry
Transchelation and Transmetallation Studies
Aliquots of [ 68 Ga]NODAGA-peptide and DOTA-peptide solutions (0.3 ml,~1.5 MBq) were mixed with (1) 0.3 ml of 0.9 % NaCl, (2) 0.3 ml of 100 nM Fe 3+ /Zn 2+ /Ca 2+ ionic salt solution (to measure transmetallation), and (3) 0.3 ml of a 200 μM DTPA solution, or with 0.3 ml of a 50-μM transferrin solution (to measure transchelation). The mixtures were incubated at 37°C and analyzed at 5, 15, 30, 60, and 120 min of incubation, 10 μl (in 100 μl of normal saline) aliquots of preparations (1), and (2) were used for radio-HPLC, while preparation (3) was analyzed by ITLC using aqueous 0.1 M citric acid as a solvent.
Stability Studies (ex vivo and in vivo)
For testing ex vivo stability, fresh cardiac blood was collected (n = 3) in heparinized vials after sacrificing athymic nude mice. The blood was centrifuged at 3000×g for 10 min at room temperature to separate the plasma. Urine was collected from the bladders. Twenty microliters of [ 68 Ga]NODAGA-peptide and DOTA-peptide was mixed with 180 μl of plasma or urine and incubated for 5, 15, 30, and 60 min at 37°C in a water bath. An equal volume of separated plasma or urine and chloroform/methanol (4:1, v/v) were mixed and centrifuged at 6000×g for 5 min to precipitate the proteins. The supernatant was used for HPLC analysis.
For testing in vivo stability, 100 ± 20 μCi of [ 68 Ga]NODAGA and DOTA-peptide conjugate was injected intravenously (i.v.) into athymic nude mice (n = 3). Blood samples (into heparinized vials) and urine samples (into polymer vials) were collected at predetermined time interval (5, 15, 30 , and 60 min) and were processed using the same procedure as described above.
Cell Binding Assay and Specific Binding
Human BT474 breast tumor cells were purchased from American Type Culture Collection (ATCC). Cells were grown in the RPMI-1640 medium with 2 mM L-glutamine containing 10 mM HEPES, 1.0 mM sodium pyruvate, 1.5 g/l sodium bicarbonate, and 4.5 g/l glucose, supplemented with 0.2 U/ml of 90 % bovine insulin and 10 % fetal bovine serum in a T75 flask, which was placed in a humidified incubator at 37°C under 5 % CO 2 /95 % air. The cells, when confluent, were detached using 0.25 % trypsin-EDTA, washed, and re-suspended in RPMI 1640 medium. The cells were centrifuged at 3000×g for 10 min and pellet was resuspended in phosphate buffered saline (pH-7.0), at a concentration of~5 × 10 6 cells/ml. Each test tube contained 1 ml of cell suspension into which 10 μl (≈ 0. Non-specific binding was calculated by incubating 1 ml of BT474 cell suspension (~5 × 10 6 cells/ml) in triplicate (n = 3) with a 400-fold excess of non-radioactive NODAGApeptide or DOTA-peptide for 15 min at 37°C in a water bath. After incubation, 10 μl of [ 68 Ga]NODAGA-peptide and DOTA-peptide (≈ 0.74 MBq) was added to each vial. The mixtures with labeled peptides were further incubated for 15, 30, 60, and 120 min at 37°C. The incubation was terminated by adding 0.5 ml of cold normal saline. The mixtures were centrifuged at 3000×g for 10 min. The supernatant from each wash was collected into marked test tubes. The pellet was washed thrice with normal saline and supernatants were collected separately in marked tubes. The radioactivity associated with cells and supernatant was counted in a gamma counter (Wizard 2 2480, Perkin Elmer) and the percentage of radioactivity bound to the cells was calculated. The specific binding was determined by subtracting the non-specific binding from total binding.
Animal Studies
PET/CT Imaging and Tissue Distribution Tumor xenografts were generated by subcutaneously injecting approximately 1.5 × 10 6 BT474 cells, suspended in 100 μl serumfree medium supplemented with Matrigel, into the right thigh of 6-8 week old, female, athymic nude mice (n = 20). When tumors had grown to a diameter of 6-8 mm (usually 4-6 weeks after inoculation), 100 ± 20 μCi of [ 68 Ga ]GaCl 3 as a control were injected i.v. into tail vein of each mouse (n = 5 per group) and 60 min later subjected to PET/CT imaging. In another group of mice bearing tumor BT474 xenografts (n = 5), 100 μg of cold peptide was administered i.v. 30 min prior the injection of [ 68 Ga]peptide conjugate in order to block the VPAC receptors. Briefly, 100 ± 20 μCi of [ 68 Ga]NODAGA-peptide was then injected i.v. in the tail vein and PET/CT imaging was performed at 1 h post-injection. A low-dose CT scan without contrast agent was acquired for anatomic localization and attenuation correction. The CT scan was acquired in step-and-shoot acquisition mode with full rotation at 360 projections. The exposure X-ray settings were set to a voltage of 80 kV and a current of 500 μA. The whole body PET scan was acquired from head to tail at 2-3 min per bed position in 3-dimensional mode. Inveon Research Workplace, version 4.2 (Siemens, Knoxville, TN), was used for image processing and analysis. An automatic rigid registration algorithm with weighted mutual information as a measure of similarity was used for registering PET and CT datasets. An orderedsubset expectation maximization (OSEM) 3-dimensional (3D) algorithm with five iterations and eight subsets was used for reconstruction. The standardized uptake value (SUV) was calculated for each organ.
Mice were then euthanized by carbon dioxide inhalation, and tissues were dissected, washed free of blood, dried, and weighed. Concomitant radioactivity was counted together with a Ga-68 standard; and injected dose per gram (% ID/g) was then calculated.
Results
Purity of Peptide-Chelator Conjugates
The chemical purity of NODAGA-peptide and DOTApeptide conjugates was greater than 95.0 %. The molecular mass for the NODAGA-peptide conjugate was 3716 Da vs. the calculated molecular mass of 3718 Da. For the DOTApeptide conjugate, observed mass was 3787 vs. the calculated molecular mass of 3785 Da. The MALDI mass spectra for the peptide conjugates are shown in Fig. 1 .
Radiochemical Purity
The radiochemical purity as analyzed by radio-high performance liquid chromatography (HPLC) was 96.3 ± 0.5 % for [ 68 Ga ]-NODAGA-peptide and 92.7 ± 5.8 % for [ 68 Ga ]DOTA-peptide. The retention time for the [ 6 8 Ga]NODAGA-peptide and DOTA-peptide was 10.2 ± 0.3 min, whereas for [ 6 8 Ga]GaCl 3 was 3.4 ± 0.4 min (Fig. 2) 
Transchelation and Transmetallation Study
Both the [ 68 Ga]NODAGA-peptide and DOTA-peptide were stable in 0.9 % normal saline and showed (G 2 %) transmetallation with FeCl 3 , CaCl 2 , and ZnCl 2 at 4 h incubation. The transchelation study with DTPA and transferrin solution showed that both radio complexes remained intact over four incubation time. ITLC showed a ratio factor value of 0.0-0.1 for the [ 68 Ga]NODAGApeptide and DOTA-peptide and 0.9-1.0 for [ 68 Ga]GaCl 3 .
Stability (ex vivo and in vivo)
The ex vivo stability examined in plasma and urine at specified time intervals at 37°C for [ 68 Ga]NODAGApeptide showed a reduction to 45.2 ± 1.8 % at 5 min and then remained the same (42.1 ± 3.7 %) at 60 min. For the [ 68 Ga ]DOTA-peptide, the radioactivity de-chelated rapidly down to 4.9 ± 0.9 % at 5 min and further degraded to 1.4 ± 0.3 % at 60 min. In urine, [ 68 Ga]NODAGA-peptide retained 41.2 ± 2.3 % radioactivity at 5 min and slightly decreased further to 37.4 ± 2.9 % at 60 min. [ 68 Ga]DOTA-peptide radioactivity was only 6.1 ± 1.1 % at 5 min and further decreased to 4.2 ± 0.4 % at 60 min. (Table 1) . HPLC analysis of the reaction mixture performed post-incubation suggests that the radioactivity was released as ionic [ 68 Ga](III) (Fig. 3a, b) .
The in vivo stability in plasma at 37°C showed a different pattern than ex vivo stability; [ 68 Ga]NODAGApeptide degraded to 6.9 ± 0.9 % at 5 min and further decreased to 2.1 ± 0.2 % at 60 min. [ 68 Ga]DOTA-peptide degraded to 4.9 ± 0.9 % at 5 min and further reduced to 2.2 ± 0.4 %. In urine, [ 68 Ga]NODAGA-peptide was 6.1 ± 1.1 % at 5 min and further reduced to 1.4 ± 0.3 % at 60 min. [ 68 Ga ]DOTA-peptide was 2.6 ± 0.8 % at 5 min and degraded further to 1.2 ± 0.4 % at 60 min. (Table 2 ). The HPLC showed decrease in area under curve at 10.2 ± 0.3 min. 
Cell Binding Assay
The specific cell binding was calculated by subtracting the non-specific binding from total binding of [ 68 Ga]NODAGApeptide and DOTA-peptide. The non-specific binding, evaluated after incubation with excess of cold peptide, was 18.0 ± 3.2 % at 1 h and 18.1 ± 2.2 % at 2 h. The specific binding for [ 68 Ga]-NODAGA-peptide was 52.2 ± 1.1 % at 1 h and 53.9 ± 0.9 % at 2 h. For [ 68 Ga]DOTA-peptide, it was 18.2 ± 1.1 % at 1 h and 25.8 ± 1.4 % at 2 h. For [ 68 Ga ]Cl 3 , it was 18.8 ± 2.5 % at 2 h (Fig. 4) 
PET/CT Imaging and Tissue Distribution
PET/CT images were obtained on mice bearing BT474 xenografts at 1 h post-i.v. injection (Fig. 5 ). Both [ 68 Ga]NODAGA-peptide and DOTA-peptide showed major uptake in kidneys followed by the liver. On comparing the standard uptake value (SUV), the tumor to muscle (T/M) ratio was 3.4 ± 0.3 for [ 68 Ga]NODAGA-peptide as compared to 1.8 ± 0.6 for [ 68 Ga]DOTA-peptide and 1.5 ± 0.6 for [ 68 Ga (Fig. 6) showed a similar pattern of distribution as observed on PET imaging. The maximum uptake was seen in kidneys (65.3 ± 19.7 %), followed by liver (4.9 ± 1.3 %). The tumor uptake was 2.4 ± 0.3 % as compared to 0.7 ± 0.2 % in the contralateral muscle; the T/M ratio was 3.4 ± 0.3. For [ 68 Ga]DOTA-peptide (Fig. 6) , the major uptake was seen in kidneys (40.3 ± 5.8 %) followed by liver (14.3 ± 4.8 %) and blood (13.2 ± 5.8 %). The uptake in tumor was 2.9 ± 0.9 % vs. 1.8 ± 1.1 % in contralateral muscle, and thus the T/M ratio was 1.9 ± 0.9, which was significantly (p G 0.05) lower as compared to [ 68 Ga]-NODAGA-peptide. The tissue distribution of [ 68 Ga]GaCl 3 ( Fig. 6 ) showed higher uptake in the lungs (4.2 ± 2.6 %) and liver (4.3 ± 1.3 %) at 1 h. The tumor uptake was 2.2 ± 1.7 % as compared to 1.2 ± 0.4 % in contralateral muscle; T/M ratio was 1.7 ± 0.8. The tissue distribution of [ 68 Ga]NODAGA-peptide in blocked mice (Fig. 6) showed same tissue distribution pattern as of nonblocked mice. However, the uptake decreased significantly 
Discussion
Advancements in molecular imaging have contributed extensively to the early detection of BC. The development of novel radiopharmaceuticals to detect BC has showed promising results. However, an unmet need exists for development of more specific radiopharmaceuticals for early detection of oncologic diseases. Our laboratory has successfully designed and characterized a peptide that has high affinity for VPAC receptors expressed in high density on BC cells. The peptide sequence has already been given in our earlier publication [15] . The peptide was conjugated with bis(thiosemicarbazone)-[N 2 S 2 ], named as TP-3805 and radiolabeled with Cu-64. Cu-64-TP-3805 has showed success in PET imaging of BC, PC, and urothelial bladder cancer (UBC) in humans [28, 29] .
We conjugated the same peptide with two different bifunctional chelating agents (NODAGA and DOTA) to radiolabel it with Ga-68. Ga-68 was the choice of radionuclide due to its many advantages over Cu-64. Previously, we have studied the difference in the radiolabeling kinetics of [ 68 Ga]NODAGA-peptide and DOTA-peptide conjugate and found that NODAGA-peptide has more flexibility in radiolabeling with Ga-68 over wide a range of pH and temperature [13] . The possible reason for more favorable Ga-68 (III) kinetics with NODAGA is its coordination number (VI). Ga(III) uses all its coordination sites to form a complex with NODAGA, whereas with DOTA, two sites remain uncoordinated [30] .
The chemical and radiochemical purities of the Ga-68 labeled NODAGA-peptide and DOTA-peptide were greater than 95 %. No post-labeling purification was required. The current method of labeling gave three times higher specific activity (37.2 ± 2.1 GBq/μmol) as compared to our previously reported method (12.6 ± 0.4 GBq/μmol) [13] . However, the actual specific activity would be very high if calculated by the HPLC method, which determines the exact amount of labeled peptide. Higher specific activity shows high uptake in small tumor tissue compartments [31] . Both radio complexes were stable against transchelation and transmetallation. Considering ex vivo stability in plasma and urine, [ 68 Ga ]ECC using fresh human serum [35] . Many studies have used either HPLC or TLC method to test the in vivo and ex vivo stability [36] [37] [38] [39] [40] [41] . We have precipitated plasma proteins using chloroform/ethanol (4/1) and analyzed the supernatant by HPLC. The HPLC (Fig. 3 ) from plasma and serum showed a peak at 3.4 ± 0.4 min which indicated free Ga-68 ( Fig. 2 ) dechelated (9 90 %) from the complex. At retention time 10.2 ± 0.3, the UV/Vis detector showed elution of the peptide conjugate which confirmed Ga-68 dechelating from the complex. A further detailed investigation is needed to find out the exact reason for such low in vivo instability.
The cell binding was studied in human BT474 breast cancer cells, showing higher 53.9 ± 0.8 % affinity for [ 68 3 (1.5 ± 0.6). The images (Fig. 5) showed renal clearance of [ 68 Ga]NODAGA-peptide and DOTA-peptide with elimination of Ga-68 through the bladder. The excretion of the radioactivity through renal system helps in rapid elimination from background tissues, which facilitates delineation of BC and reduces the radiation burden. The kidneys however are the major dose limiting organ. The tissue distribution (Fig.  6) showed a similar distribution pattern as observed in PET images. [ 68 Ga]NODAGA showed higher T/M ratio (3.4 ± 0.3) as compared to 1.9 ± 0.9 for [ 68 Ga]DOTApeptide and 1.7 ± 0.8 for [ 68 Ga]GaCl 3. The receptor blocking studies showed a similar pattern of tissue distribution but lower T/M ratio (1.7 ± 0.3) as compared to those in nonblocked mice (3.4 ± 0.3), which suggested the specificity of [ 68 Ga]NODAGA-peptide towards VPAC expressing tumors.
However, the uptake of [ 68 Ga]NODAGA-peptide conjugate in tumor mice was not significantly higher as expected after observing the in vitro cell binding data; this may be due to low in vivo stability. In the same peptide conjugated to a different chelating agent, a different distribution was observed. This may be due to change in the overall biological properties of the molecule after conjugation and radiolabeling. The overall chemical structure of the compound may be responsible for in vivo distribution of the [ 68 Ga ]NODAGA-peptide and DOTA-peptide [42] . Although both agents have relatively low in vivo stability, the studies suggested that [ 68 Ga]NODAGA-peptide has relatively better stability and greater affinity for VPAC-expressing BT474 breast cancer cells than [ 68 Ga]DOTA-peptide.
Conclusion
The post-processing of [ 68 Ga]GaCl 3 ensured removal of cationic impurities and yielded a higher radiochemical purity. The labeling method was reproducible and yielded higher specific activity for [ 68 
